RESUMEN
BACKGROUND/AIMS@#The occurrence of brain metastasis (BM) has increased due to improved overall survival (OS) in uterine cervical cancer. However, research about prognostic factors and therapeutic guidelines for BM in uterine cervical cancer remains scarce due to the rarity of BM in this type of cancer. The present study evaluated the clinical characteristics and prognostic factors influencing OS in patients with BM from uterine cervical cancer.@*METHODS@#A total of 19 BM patients of uterine cervical cancer were analyzed retrospectively from January 1995 to December 2016.@*RESULTS@#The median and mean OS of all patients was 9.6 and 15.4 months. Treatment (vs. palliative care, p < 0.001), fewer than three regimens of chemotherapy before BM (vs. ≥ 3, p < 0.013), and chemotherapy after BM (vs. absence, p < 0.001) significantly increased the OS time. The Karnofsky performance status ≥ 70 (vs. < 70, p = 0.213), single BM (vs. multiple BM, p = 0.157), and small cell carcinoma (vs. others, p = 0.351) had numerically higher OS than others. Dual therapy (vs. single therapy, p = 0.182; vs. no therapy, p = 0.076) were associated with a longer OS time, but the difference did not reach statistical significance. In addition, the graded prognostic assessment (GPA) appeared to be a better prognostic tool than the recursive partitioning analysis.@*CONCLUSIONS@#The results of the present study suggest active multimodal treatment including neurosurgery, radiotherapy, and chemotherapy for BM of uterine cervical cancer with single BM, good performance status, histology of small cell carcinoma, and a better GPA.
RESUMEN
Neurofibromatosis type 1 (NF1) is a genetic disease characterized by neoplastic and non-neoplastic disorders involving tissues of neuroectodermal and mesenchymal origin. NF1 is caused by mutations in the NF1 gene, which is found on chromosome 17q11.2. Patients with NF1 are at increased risk of developing soft tissue sarcomas that arise within the stromal compartment of the gastrointestinal tract, termed gastrointestinal stromal tumors (GISTs). GISTs associated with neurofibromatosis differ from sporadic GISTs, particularly with respect to their lower response rate to imatinib. We recently experienced a case involving a 45-year-old man with NF1 who was admitted to the hospital with epigastric pain and vomiting. Abdominal computed tomography revealed a duodenal GIST with pancreatic invasion. He had a base substitution mutation involving replacement of 2041 cytosine with thymine. He was treated successfully with a surgical operation and adjuvant imatinib therapy.
Asunto(s)
Humanos , Persona de Mediana Edad , Benzamidas , Citosina , Tumores del Estroma Gastrointestinal , Tracto Gastrointestinal , Genes de Neurofibromatosis 1 , Placa Neural , Neurofibromatosis , Neurofibromatosis 1 , Piperazinas , Pirimidinas , Sarcoma , Timina , Vómitos , Mesilato de ImatinibRESUMEN
Neurofibromatosis type 1 (NF1) is a genetic disease characterized by neoplastic and non-neoplastic disorders involving tissues of neuroectodermal and mesenchymal origin. NF1 is caused by mutations in the NF1 gene, which is found on chromosome 17q11.2. Patients with NF1 are at increased risk of developing soft tissue sarcomas that arise within the stromal compartment of the gastrointestinal tract, termed gastrointestinal stromal tumors (GISTs). GISTs associated with neurofibromatosis differ from sporadic GISTs, particularly with respect to their lower response rate to imatinib. We recently experienced a case involving a 45-year-old man with NF1 who was admitted to the hospital with epigastric pain and vomiting. Abdominal computed tomography revealed a duodenal GIST with pancreatic invasion. He had a base substitution mutation involving replacement of 2041 cytosine with thymine. He was treated successfully with a surgical operation and adjuvant imatinib therapy.
Asunto(s)
Humanos , Persona de Mediana Edad , Benzamidas , Citosina , Tumores del Estroma Gastrointestinal , Tracto Gastrointestinal , Genes de Neurofibromatosis 1 , Placa Neural , Neurofibromatosis , Neurofibromatosis 1 , Piperazinas , Pirimidinas , Sarcoma , Timina , Vómitos , Mesilato de ImatinibRESUMEN
Sertoli-Leydig cell tumor is an uncommon tumor that may manifest itself by a characteri-stic virilization symptom. It is a rare gonadal tumor of sex-cord type, representing only 0.1~0.5% of all primary ovarian neoplasm. These tumors are the most common virilizing tumors in women of reproductive age. However, only one-third of patients develop masculinization. We have seen two cases of Sertoli-Leydig cell tumors without the virilizing symptom. These two cases have been confirmed by permanent tissue biopsies and have been presented in a 32-year old female who has had only amenorrhea and in a 56-year old postmenopausal female who has not manifested virilizing symptom. These cases are presented with brief review of the literature.